Reliant AI, a data analytics software provider based in Montreal, Canada, and Berlin Germany was Founded by Karl Moritz Hermann, Marc Bellemare, and Richard Schlegel. Reliant AI specializes in generative AI-powered data analytics, designed to accelerate secondary research in the biopharmaceutical industry. Their flagship product, Reliant Tabular, serves as an AI-driven work tool developed for life science analysts. The platform assists users in conducting automated systematic reviews, asset scans, comprehensive data analyses, and creating custom data platforms, all aimed at helping analysts find vital scientific evidence for their decision-making processes.
Key features of Reliant Tabular include:
– Proprietary machine learning models fine-tuned for biopharma-specific topics.
– A thorough approach to fact-finding, ensuring maximum recall so no critical data is overlooked.
– A user-friendly interface that facilitates quick reconciliation of generated results with ground truth evidence.
– Report-ready output formats that enable seamless team collaboration on complex analyses.
The company recently announced that it has successfully raised $11.3 million in Seed funding. The funding round was led by Tola Capital and Inovia Capital, with additional support from angel investor Mike Volpi.
The company plans to utilize the new capital to expand its engineering team and enhance its technological capabilities, focusing on growing its presence across Europe and North America.
Reliant Tabular is already attracting considerable attention across various sectors within the biopharma industry, signaling strong market potential for the company’s innovative solutions.
